此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Combined Metabolic Activator Supplementation in Subjects Diagnosed With Gout

2026年11月19日 更新者:ScandiBio Therapeutics AB

A Phase 3, Randomised, Double-Blind, Placebo-Controlled, Multi-centre Study to Evaluate the Efficacy, Safety, and Tolerability of Combined Metabolic Activator (CMA2) Supplementation in Individuals With Hyperuricemia Associated With Gout

This will be a randomised, double-blind, placebo-controlled, multi-centre study with the aim to establish metabolic improvements in individuals diagnosed with hyperuricemia associated with gout by treatment with CMA2 including N-acetyl-L-cysteine (NAC), L-carnitine-L-tartrate (LCAT), nicotinamide (niacinamide), and L-serine for 4 weeks.

研究概览

详细说明

Consenting participants will be screened for eligibility (Visit 1; screening) according to study-specific eligibility criteria within 7 days prior to randomisation and start of investigational medicinal product (IMP) administration.

Eligible participants will be randomised on Day 1 (Visit 2) to 4 weeks of twice daily (b.i.d.) oral treatment of either CMA2 or placebo (1:1). The first dose will be administered at the study clinic. The participants will be observed for 2 hours post dose for the development of any allergic reactions or intolerance after taking the first dose.

Visits at the study site will be performed at Day 1 (Visit 2), Day 14 (Visit 4) and Day 28 (Visit 6; end of in study treatment). There will be telephone follow up visits at Day 7 (Visit 3) and Day 21(Visit 5) checking safety, concomitant medications and IMP compliance. A final follow-up visit for safety assessments will be conducted in a subgroup of patients 14 days after the end of treatment (Day 42; Visit 7) during an IMP-free follow-up period to assess safety and concomitant medications.

The following clinical scales will be used to evaluate the effect of CMA2 on uric acid decline, hsCRP and daily life activity: Serum Uric Acid Levels, hsCRP, number of flares according to the GAFFO criteria, HAQ-DI, SF-36, PGA (100 mm).

Plasma samples will be collected for advanced metabolomics, proteomics, and lipidomics analysis.

Optionally, synovial samples will be collected for advanced metabolomics, proteomics, and lipidomics analysis. Optionally, gut and saliva samples will be collected for metagenomics analysis of gut and oral microbiome.

Laboratory and clinical safety parameters will be monitored at pre-specified time-points.

研究类型

介入性

注册 (估计的)

336

阶段

  • 第三阶段

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

  • 姓名:Gökhan Gönenli, Uzm. Dr. M.
  • 电话号码:+ 90 532 405 76 82
  • 邮箱:mgonenli@ku.edu.tr

研究联系人备份

  • 姓名:Müjdat Zeybel, Prof. Dr.
  • 电话号码:+ 90 532 604 83 81
  • 邮箱:mzeybel@ku.edu.tr

学习地点

      • Ankara、土耳其(türkiye)
        • 尚未招聘
        • Ankara Bilkent City Hospital
        • 接触:
          • Hakan Babaoğlu
        • 首席研究员:
          • Hakan Babaoğlu, Assoc. Prof. Dr.
      • Antalya、土耳其(türkiye)
        • 尚未招聘
        • Alanya Training and Research Hospital
        • 接触:
          • Şakir Özgür Keskek
        • 首席研究员:
          • Şakir Özgür Keskek, Prof. Dr.
      • Erzurum、土耳其(türkiye)
        • 尚未招聘
        • Atatürk University Research Hospital
        • 接触:
          • Bülent Albayrak
        • 首席研究员:
          • Bülent Albayrak, Assoc. Prof. Dr.
      • Erzurum、土耳其(türkiye)
        • 尚未招聘
        • Erzurum City Hospital
        • 接触:
          • Kenan Çadırcı
        • 首席研究员:
          • Kenan Çadırcı, Prof. Dr.
      • Eskişehir、土耳其(türkiye)
        • 招聘中
        • Eskişehir Osmangazi University Faculty of Medicine Hospital
        • 接触:
          • Nazife Şule Bige Yaşar
        • 首席研究员:
          • Nazife Şule Bige Yaşar, Prof. Dr.
      • Istanbul、土耳其(türkiye)
        • 尚未招聘
        • Göztepe Prof. Dr. Süleyman Yalçın City Hospital
        • 接触:
          • Esen Kasapoğlu
        • 首席研究员:
          • Esen Kasapoğlu, Prof. Dr.
      • Istanbul、土耳其(türkiye)
        • 尚未招聘
        • Istanbul University-Cerrahpaşa Faculty of Medicine Hospital
        • 接触:
          • Gülen Hatemi
        • 首席研究员:
          • Gülen Hatemi, Prof. Dr.
      • Istanbul、土耳其(türkiye)
        • 尚未招聘
        • Kanuni Sultan Süleyman Training and Research Hospital
        • 接触:
          • Ozan Cemal İçaçan
        • 首席研究员:
          • Ozan Cemal İçaçan, Specialist. Dr.
      • Istanbul、土耳其(türkiye)
        • 尚未招聘
        • Kartal Dr. Lütfi Kırdar City Hospital
        • 接触:
          • Mehmet Engin Tezcan
        • 首席研究员:
          • Mehmet Engin Tezcan, Specialist. Dr.
      • Istanbul、土耳其(türkiye)
        • 招聘中
        • Koç University Hospital
        • 接触:
        • 首席研究员:
          • Gökhan Gönenli, Specialist. Dr.
      • Istanbul、土耳其(türkiye)
        • 尚未招聘
        • Sancaktepe Şehit Prof. Dr. İlhan Varank Training and Research Hospital
        • 接触:
          • Kadem Arslan
        • 首席研究员:
          • Kadem Arslan, Assoc. Prof. Dr.
      • Istanbul、土耳其(türkiye)
        • 尚未招聘
        • Sultan 2nd Abdülhamid Han Training and Research Hospital
        • 接触:
          • Memnune Sena Ulu
        • 首席研究员:
          • Memnune Sena Ulu, Prof. Dr.

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  1. Men and women ≥ 18 years of age.
  2. Individuals with elevated uric acid blood levels (7 mg/dl) and at least one episode of gout during the last three years.
  3. Diagnosis of gout based on 2015 American College of Rheumatology-European Union League Against Rheumatism (ACR-EULAR) criteria.
  4. Able to give written informed consent for participation in the study by the patient and/or legal representatives.

Exclusion Criteria:

  1. Patients who have received uric acid-lowering therapy with a change in dose within 1 month prior to inclusion.

  2. Acute gout flare within 14 days prior to randomization (i.e., any gouty arthritis episode with pain or swelling that has not fully resolved ≤14 days before randomization). Definition of Resolved (for the eligibility assessment): absence of joint pain at rest and no visible swelling at the previously affected joint(s) for at least 48 hours, and no requirement for escalation of anti-inflammatory therapy within that period.

  3. History of stroke.

  4. History of brain trauma < 14 days.

  5. Uncontrolled diagnosed depression.

  6. Uncontrolled diabetes (HbA1c > 8.4%).

  7. Severe swallowing problems.

  8. PEG-feeding.

  9. Chronic diarrhoea.

  10. Chronic kidney disease with S-creatinine > 1.30 mg/dL.

  11. Estimated glomerular filtration rate (eGFR) of <30 mL/min/1.73 m2 in the Screening Phase

  12. Active bronchial asthma at the time of screening.

  13. History of phenylketonuria

  14. Known allergy for substances used in the study

  15. Known allergy for strawberry

  16. Known active malignancy

  17. Known active psoriasis

  18. Use of dietary supplements such as vitamins, omega-3 products, or plant stanol/sterol products later than one (1) week prior to inclusion.

  19. Use of anti-microbial agents later than one (1) week prior to inclusion.

  20. Drug and/or alcohol abuse.

  21. Participants considered as inappropriate for this study for any reason (noncompliance etc.) per investigator assessment.

  22. Administration of another new chemical entity (defined as a compound that has not been approved for marketing) or has participated in any other clinical study that included drug treatment with the last administration within 3 months prior to administration of IMP in this study.

  23. Females who are breastfeeding or pregnant at screening (as documented by a positive beta human chorionic gonadotropin [β-hCG] test)

  24. Females of childbearing potential who:

    Within 28 days before study entry, did not use a highly effective method of contraception, which includes any of the following:

    • total abstinence (if it is their preferred and usual lifestyle)
    • an intrauterine device or intrauterine hormone-releasing system (IUS)
    • a contraceptive implant
    • an oral contraceptive (Subject must have been on a stable dose of the same oral contraceptive product for at least 28 days before dosing and must agree to stay on the same dose of the oral contraceptive throughout the study and for 28 days after study drug discontinuation.)
    • have a vasectomized partner with confirmed azoospermia. Do not agree to use a highly effective method of contraception (as described above) throughout the entire study period and for 28 days after study drug discontinuation.

    It is permissible that if a highly effective method of contraception is not appropriate or acceptable to the subject, then the subject must agree to use a medically acceptable method of contraception, ie, double-barrier methods of contraception such as latex or synthetic condom plus diaphragm or cervical/vault cap with spermicide.

    NOTE: Females of childbearing potential must have documented tubal ligation or hysterectomy; or be post-menopausal (defined as 12 months of amenorrhea [in questionable cases a blood sample with simultaneous follicle stimulating hormone (FSH) 25-140 IE/L and estradiol <200 pmol/L is confirmatory]).

  25. Male participants who:

    1. Plan to conceive a child or donate sperm during the study treatment period and for at least 90 days after the last dose of investigational product, or
    2. Are unwilling to use effective contraception during the study and for at least 90 days after the last dose of investigational product.
  26. Currently has secondary hyperuricemia:

1) Lesch-Nyhan syndrome 2) Phosphoribosylpyrophosphate synthetase superactivity 3) Congenital myogenic hyperuricemia 4) Hematopoietic neoplasms (acute leukemia, lymphoma malignant, myeloproliferative disorder, myelodysplastic syndrome, etc) 5) Solid tumors (breast cancer, seminoma, sarcoma, Wilms tumor, small cell lung cancer, etc) 6) Non-neoplastic diseases (psoriasis vulgaris, secondary polycythemia, hemolytic anemia) 7) Rhabdomyolysis 8) Hypothyroidism 9) Polycystic kidney 10) Lead poisoning/lead nephropathy 11) Down's syndrome 12) Familial juvenile gouty nephropathy 13) Hyperlactacidemia 14) Glycogen storage disease type 1 27. Participants who are on the following treatment are required to be on a stable dose and same mode of administration for at least 14 days prior to screening and to keep the stable during the study. Participants are not permitted to initiate these drugs within 14 days prior to screening and during the study.

  • Dietary and physical therapy for the underlying disease
  • Drugs or containing compound preparations that potentially affect SUA level:
  • Immunosuppressants (mizoribine, cyclosporin, tacrolimus hydrate)
  • Antituberculous drugs (pyrazinamide, ethambutol hydrochloride)
  • Hyperlipidemia drugs (fenofibrate, atorvastatin, rosuvastatin, pitavastatin)
  • Antihypertensives (losartan potassium)
  • Diuretics (thiazide diuretics, loop diuretics)
  • Sodium-dependent glucose transporter (SGLT) 2 inhibitors
  • Theophylline

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:支持治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:双倍的

武器和干预

参与者组/臂
干预/治疗
实验性的:治疗臂

A total of 20g of CMA2 with strawberry aroma and colouring agent will be given. The IMP will be provided as a soluble powder packed as individual dosages in identical sachets. The powder should be dissolved in 200 ml preferably cold water before use. The powder can also be used on yoghurt or other food. The subjects will take two daily oral doses of the IMP, one dose just after breakfast and one dose just after dinner. Subjects who cannot tolerate (e.g., diarrhoea) taking full dose will be withdrawn from the study.

安慰剂比较:安慰剂组

As placebo, a total of 20g of compound primarily containing collagen and maltodextrin will be administered. Placebo contains strawberry aroma flavouring and colouring agent.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
To evaluate the effect of 4-weeks administration of CMA2 treatment on serum uric acid levels in participants diagnosed with hyperuricemia associated with gout, as compared with placebo.
大体时间:4 weeks

Absolute change in serum uric acid levels from baseline to end-of-treatment (4 weeks).

4 weeks

次要结果测量

结果测量
措施说明
大体时间
To evaluate the effect of 4 weeks of CMA2 treatment on patient global assessment (PGA, 100 mm) compared with placebo.
大体时间:4 weeks

Change in Patient Global Assessment (PGA, 100 mm) score from baseline to end-of-treatment. PGA is assessed using a visual analogue scale (VAS) ranging from 0 to 10 or 0 to 100, where higher scores indicate worse disease activity.

4 weeks
To evaluate the effect of 4 weeks of CMA2 treatment on High Sensitivity C-reactive Protein (hsCRP) levels compared with placebo.
大体时间:4 weeks

Percentage change in High Sensitivity C-reactive Protein (hsCRP) levels from baseline to end-of-treatment.

4 weeks
To evaluate the proportion of participants achieving serum uric acid levels < 6 mg/dL.
大体时间:4 weeks

Proportion of patients with a serum uric acid level <6 .0 mg/dL at end-of-treatment.

4 weeks
To evaluate the effect of 2-weeks administration of CMA2 treatment on serum uric acid levels compared with placebo.
大体时间:2 weeks

Change in serum uric acid levels from baseline to 2-weeks.

2 weeks
To evaluate patient adherence to the twice-daily treatment regimen.
大体时间:4 weeks

Percentage of expected twice-daily study drug doses successfully administered, as assessed by sachet counts.

4 weeks
To evaluate the incidence of adverse events (AEs).
大体时间:6 weeks

The percentage of subjects experiencing at least one AE during the study period.

6 weeks
To evaluate the severity of AEs.
大体时间:6 weeks

The incidence of AEs categorized by maximum severity grade.

6 weeks
To evaluate the incidence of serious adverse events (SAEs).
大体时间:6 weeks

The percentage of subjects experiencing at least one SAE during the study period.

6 weeks

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Gökhan Gönenli, Uzm. Dr. M.、Koc University Hospital

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2026年11月4日

初级完成 (估计的)

2027年2月1日

研究完成 (估计的)

2027年2月1日

研究注册日期

首次提交

2026年10月15日

首先提交符合 QC 标准的

2026年10月15日

首次发布 (实际的)

2026年10月22日

研究记录更新

最后更新发布 (实际的)

2026年11月20日

上次提交的符合 QC 标准的更新

2026年11月19日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅